文献速递真菌感染细菌感染、耐药与抗菌药物

血液病患者伏立康唑耐药侵袭性曲霉病的患病率及其对死亡率的影响

Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该多中心回顾性研究分析了129例培养阳性的血液病患者侵袭性曲霉病(IA),其中伏立康唑耐药占20.2%。耐药组12周总死亡率在非ICU患者中显著高于敏感组(54.4% vs 30.7%,P=0.035),ICU患者死亡率普遍极高。

要点

  • 血液病培养阳性IA中伏立康唑耐药率高达20.2%。
  • 非ICU耐药IA患者12周死亡率显著高于敏感株IA。
  • ICU患者无论耐药与否死亡率均极高。

核心结论

  • 血液病培养阳性IA患者中伏立康唑耐药率很高(20.2%)。
  • 非ICU患者中,伏立康唑耐药IA的12周总死亡率显著高于敏感IA(54.4% vs 30.7%,P=0.035)。

研究设计与样本

  • 多中心回顾性研究,纳入129例培养阳性的血液病确诊/临床诊断IA患者。
  • 按EUCAST肉汤微量稀释法测定的伏立康唑敏感性分层,比较真菌学与临床数据及6周、12周生存率。

主要发现

  • 129例中伏立康唑敏感103例(79.8%),耐药26例(20.2%)。
  • 75.0%(97/129)患者起始接受三唑类单药治疗。
  • 全部患者中,耐药组6周死亡率42.3% vs 敏感组28.2%(P=0.20),12周57.7% vs 36.9%(P=0.064)。
  • 非ICU患者中,耐药组6周死亡率36.4% vs 21.6%(P=0.16),12周54.4% vs 30.7%(P=0.035)。

临床怎么用

  • 对血液病培养阳性IA患者应关注伏立康唑耐药可能,尤其非ICU患者。
  • 耐药IA与非ICU患者12周死亡率升高相关,需考虑早期耐药检测和调整治疗。

局限性

  • 回顾性研究设计。
  • 仅纳入培养阳性IA病例,可能低估总IA人群。
  • 部分死亡率比较未达统计学显著性(如全部患者6周和12周比较)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing resistance of Aspergillus fumigatus to triazoles in high-risk populations is a concern. Its impact on mortality is not well understood, but rates from 50% to 100% have been reported. OBJECTIVES: To determine the prevalence of voriconazole-resistant A. fumigatus invasive aspergillosis (IA) and its associated mortality in a large multicentre cohort of haematology patients with culture-positive IA. METHODS: We performed a multicentre retrospective study, in which outcomes of culture-positive haematology patients with proven/probable IA were analysed. Patients were stratified based on the voriconazole susceptibility of their isolates (EUCAST broth microdilution test). Mycological and clinical data were compared, along with survival at 6 and 12 weeks. RESULTS: We identified 129 A. fumigatus culture-positive proven or probable IA cases; 103 were voriconazole susceptible (79.8%) and 26 were voriconazole resistant (20.2%). All but one resistant case harboured environment-associated resistance mutations in the cyp51A gene: TR34/L98H (13 cases) and TR46/Y121F/T289A (12 cases). Triazole monotherapy was started in 75.0% (97/129) of patients. Mortality at 6 and 12 weeks was higher in voriconazole-resistant cases in all patients (42.3% versus 28.2%, P = 0.20; and 57.7% versus 36.9%, P = 0.064) and in non-ICU patients (36.4% versus 21.6%, P = 0.16; and 54.4% versus 30.7%; P = 0.035), compared with susceptible ones. ICU patient mortality at 6 and 12 weeks was very high regardless of triazole susceptibility (75.0% versus 66.7%, P = 0.99; and 75.0% versus 73.3%, P = 0.99). CONCLUSIONS: A very high prevalence of voriconazole resistance among culture-positive IA haematology patients was observed. The overall mortality at 12 weeks was significantly higher in non-ICU patients with voriconazole-resistant IA compared with voriconazole-susceptible IA.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Resendiz-Sharpe A, Mercier T, Lestrade PPA, et al. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. J Antimicrob Chemother. 2019. PMID: 31236587. doi:10.1093/jac/dkz258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。